Akebia Therapeutics (AKBA) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SIGA Technologies (SIGA) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 60.4% versus a loss of 71.4%. Over five years, SIGA leads with a -53.9% price change compared with -71.4% for AKBA. SIGA Technologies is the larger company by market cap ($235.7 million vs $225.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | SIGA |
|---|---|---|
| Share price | $0.8148 | $3.28 |
| Market cap | $225.79M | $235.67M |
| 1-day change | -6.71% | +0.61% |
| YTD return | -49.39% | -46.32% |
| 1-year return | -71.41% | -60.39% |
| 5-year return | -71.41% | -53.87% |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $-0.12 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $8.55 |
| 52-week low | $0.814 | $2.83 |
| Distance from 52-week high | -74.54% | -61.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.10% | — |
| Average volume | 6.18M | 726.75K |
| Shares outstanding | 277.11M | 71.85M |
| Employees | 194 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIGA has outperformed AKBA by 11.0 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AKBA vs SIGA FAQ
Which is bigger, Akebia Therapeutics or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $235.67M compared with $225.79M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or SIGA?
SIGA returned -60.39% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.